Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.57 |
| ▸ | BPTF | Q12830 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852275 | 0.89 | CHRNB2 (0.62) | CHRNB4CHRNA3BPTFCHRNB2CHRNA4 | |
| SCHEMBL19839303 | 0.89 | CHRNB2 (0.62) | CHRNB4CHRNA3BPTFCHRNB2CHRNA4 | |
| SCHEMBL31127631 | 0.77 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL12663143 | 0.76 | BPTF (0.53) | CHRNA3BPTFCHRNB2CHRNA4HTR3E | |
| SCHEMBL800968 | 0.76 | BPTF (0.53) | CHRNA3BPTFCHRNB2CHRNA4HTR3E | |
| SCHEMBL8342001 | 0.76 | BPTF (0.53) | CHRNB4CHRNA3BPTFCHRNB2CHRNA4 | |
| SCHEMBL5995974 | 0.74 | CHRNB4 (1.00) | CHRNB4CHRNA3 | |
| SCHEMBL24989415 | 0.74 | HRH3 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22187756 | 0.73 | NOTUM (0.51) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL24243037 | 0.73 | CHRNB4 (0.42) | CHRNB4CHRNA3CHRNB2CHRNA4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CHRNB4 97/4885CHRNA3 61/4885BPTF 2707/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CHRNB4 97/4885CHRNA3 61/4885BPTF 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.